Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 858293, 11 pages
http://dx.doi.org/10.1155/2014/858293
Review Article

Functional Stability of Plasminogen Activator Inhibitor-1

1Department of Bioengineering, Marmara University, 34722 Istanbul, Turkey
2Department of Cardiology, Faculty of Medicine, Marmara University, Selimiye M. Tibbiye C. No. 38, Haydarpasa, 34668 Istanbul, Turkey

Received 30 July 2014; Accepted 17 September 2014; Published 15 October 2014

Academic Editor: Nejat Akar

Copyright © 2014 Songul Yasar Yildiz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Gils and P. J. Declerck, “The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors,” Thrombosis and Haemostasis, vol. 91, no. 3, pp. 425–437, 2004. View at Google Scholar · View at Scopus
  2. A. Gils and P. J. Declerck, “Structure-function relationships in serpins: current concepts and controversies,” Thrombosis and Haemostasis, vol. 80, no. 4, pp. 531–541, 1998. View at Google Scholar · View at Scopus
  3. G. C. Sui, H. Mångs, and B. Wiman, “The role of His143 for the pH-dependent stability of plasminogen activator inhibitor-1,” Biochimica et Biophysica Acta—Protein Structure and Molecular Enzymology, vol. 1434, no. 1, pp. 58–63, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. D. C. Rijken and H. R. Lijnen, “New insights into the molecular mechanisms of the fibrinolytic system,” Journal of Thrombosis and Haemostasis, vol. 7, no. 1, pp. 4–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Wiman, “Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease,” Thrombosis and Haemostasis, vol. 74, no. 1, pp. 71–76, 1995. View at Google Scholar · View at Scopus
  6. S. Gando, Y. Nakanishi, and I. Tedo, “Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome,” Critical Care Medicine, vol. 23, no. 11, pp. 1835–1842, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Iba, A. Kidokoro, M. Fukunaga, K. Sugiyama, T. Sawada, and H. Kato, “Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers,” Shock, vol. 23, no. 1, pp. 25–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Idell, W. Girard, K. B. Koenig, J. McLarty, and D. S. Fair, “Abnormalities of pathways of fibrin turnover in the human pleural space,” The American Review of Respiratory Disease, vol. 144, no. 1, pp. 187–194, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Semeraro, C. T. Ammollo, F. Semeraro, and M. Colucci, “Sepsis, thrombosis and organ dysfunction,” Thrombosis Research, vol. 129, no. 3, pp. 290–295, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Karandashova, G. Florova, A. O. Azghani et al., “Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacerbates tetracycline-induced pleural injury in rabbits,” The American Journal of Respiratory Cell and Molecular Biology, vol. 48, no. 1, pp. 44–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. R. D. Balsara, Z. Xu, and V. A. Ploplis, “Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice,” Current Drug Targets, vol. 8, no. 9, pp. 982–995, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. van de Craen, I. Scroyen, C. Vranckx et al., “Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1,” Thrombosis Research, vol. 129, no. 4, pp. e126–e133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Huber and R. W. Carrell, “Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins,” Biochemistry, vol. 28, no. 23, pp. 8951–8966, 1989. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Dupont, J. B. Madsen, T. Kristensen et al., “Biochemical properties of plasminogen activator inhibitor-1,” Frontiers in Bioscience, vol. 14, no. 4, pp. 1337–1361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. van Mourik, D. A. Lawrence, and D. J. Loskutoff, “Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelials cells,” The Journal of Biological Chemistry, vol. 259, no. 23, pp. 14914–14921, 1984. View at Google Scholar · View at Scopus
  16. L. S. Nielsen, P. A. Andreasen, and J. Grondahl-Hansen, “Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells—inhibitor neutralization and one-step affinity purification,” Thrombosis and Haemostasis, vol. 55, no. 2, pp. 206–212, 1986. View at Google Scholar · View at Scopus
  17. M. Philips, A.-G. Juul, S. Thorsen, J. Selmer, and J. Zeuthen, “Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta,” Thrombosis and Haemostasis, vol. 55, no. 2, pp. 213–217, 1986. View at Google Scholar · View at Scopus
  18. H. Pannekoek, H. Veerman, H. Lambers et al., “Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family,” The EMBO Journal, vol. 5, no. 10, pp. 2539–2544, 1986. View at Google Scholar · View at Scopus
  19. T. Ny, M. Sawdey, D. Lawrence, J. L. Millan, and D. J. Loskutoff, “Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 18, pp. 6776–6780, 1986. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Ginsburg, R. Zeheb, A. Y. Yang et al., “cDNA cloning of human plasminogen activator-inhibitor from endothelial cells,” Journal of Clinical Investigation, vol. 78, no. 6, pp. 1673–1680, 1986. View at Publisher · View at Google Scholar · View at Scopus
  21. P. A. Andreasen, A. Riccio, K. G. Welinder et al., “Plasminogen activator inhibitor type-1 : reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing,” FEBS Letters, vol. 209, no. 2, pp. 213–218, 1986. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Zeheb and T. D. Gelehrter, “Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1,” Gene, vol. 73, no. 2, pp. 459–468, 1988. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Mimuro and D. J. Loskutoff, “Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin,” Journal of Biological Chemistry, vol. 264, no. 2, pp. 936–939, 1989. View at Google Scholar · View at Scopus
  24. G. C. Prendergast, L. E. Diamond, D. Dahl, and M. D. Cole, “The c-myc-regulated gene mr1 encodes plasminogen activator inhibitor 1,” Molecular and Cellular Biology, vol. 10, no. 3, pp. 1265–1269, 1990. View at Google Scholar · View at Scopus
  25. K. J. Hofmann, E. J. Mayer, L. D. Schultz, S. H. Socher, and C. F. Reilly, “Purification and characterisation of recombinant rabbit plasminogen activator inhibitor-1 expressed in Saccharomyces cerevisiae,” Fibrinolysis and Proteolysis, vol. 6, no. 4, pp. 263–272, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. A. P. Bijnens, I. Knockaert, E. Cousin, E. K. O. Kruithof, and P. J. Declerck, “Expression and characterization of recombinant porcine plasminogen activator inhibitor-1,” Thrombosis and Haemostasis, vol. 77, no. 2, pp. 350–356, 1997. View at Google Scholar · View at Scopus
  27. L. M. Meissenheimer, K. Verbeke, P. J. Declerck, and A. Gils, “Quantitation of vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-I in plasma and platelets,” Thrombosis and Haemostasis, vol. 95, no. 5, pp. 902–903, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Declerck and A. Gils, “Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin,” Seminars in Thrombosis and Hemostasis, vol. 39, no. 4, pp. 356–364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. D. J. Loskutoff, M. Linders, and J. Keijer, “Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns,” Biochemistry, vol. 26, no. 13, pp. 3763–3768, 1987. View at Publisher · View at Google Scholar · View at Scopus
  30. P. J. Bosma, E. A. van den Berg, T. Kooistra, D. R. Siemieniak, and J. L. Slightom, “Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences,” Journal of Biological Chemistry, vol. 263, no. 19, pp. 9129–9141, 1988. View at Google Scholar · View at Scopus
  31. L. Strandberg, D. Lawrence, and T. Ny, “The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family,” European Journal of Biochemistry, vol. 176, no. 3, pp. 609–616, 1988. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Riccio, L. R. Lund, R. Sartorio et al., “The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene,” Nucleic Acids Research, vol. 16, no. 7, pp. 2805–2824, 1988. View at Publisher · View at Google Scholar · View at Scopus
  33. C. J. Bruzdzinski, M. Riordan-Johnson, E. C. Nordby, S. M. Suter, and T. D. Gelehrter, “Isolation and characterization of the rat plasminogen activator inhibitor-1 gene,” The Journal of Biological Chemistry, vol. 265, no. 4, pp. 2078–2085, 1990. View at Google Scholar · View at Scopus
  34. M. Colucci, J. A. Paramo, and D. Collen, “Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation,” Journal of Clinical Investigation, vol. 75, no. 3, pp. 818–824, 1985. View at Publisher · View at Google Scholar · View at Scopus
  35. D. C. Morrison and R. J. Ulevitch, “The effects of bacterial endotoxins on host mediation systems. A review,” The American Journal of Pathology, vol. 93, no. 2, pp. 526–617, 1978. View at Google Scholar · View at Scopus
  36. M. Henry, N. Chomiki, P. Y. Scarabin et al., “Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 5, pp. 851–858, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Dawson, A. Hamsten, B. Wiman, A. Henney, and S. Humphries, “Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity,” Arteriosclerosis and Thrombosis, vol. 11, no. 1, pp. 183–190, 1991. View at Publisher · View at Google Scholar · View at Scopus
  38. A. E. Tsantes, G. K. Nikolopoulos, P. G. Bagos, S. Bonovas, P. Kopterides, and G. Vaiopoulos, “The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk,” Thrombosis Research, vol. 122, no. 6, pp. 736–742, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. D. E. Vaughan, “PAI-1 and atherothrombosis,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1879–1883, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Agirbasli, “Pivotal role of plasminogen-activator inhibitor 1 in vascular disease,” International Journal of Clinical Practice, vol. 59, no. 1, pp. 102–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Agirbasli, M. Eren, F. Eren et al., “Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy,” Journal of Thrombosis and Thrombolysis, vol. 32, no. 1, pp. 59–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. I. L. Knottnerus, J. W. Govers-Riemslag, K. Hamulyak, and et al, “Endothelial activation in lacunar stroke subtypes,” Stroke, vol. 41, no. 8, pp. 1617–1622, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Libby, P. M. Ridker, and G. K. Hansson, “Inflammation in atherosclerosis: from pathophysiology to practice,” Journal of the American College of Cardiology, vol. 54, no. 23, pp. 2129–2138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Pandolfi, D. Cetrullo, R. Polishuck et al., “Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 8, pp. 1378–1382, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. M.-C. Alessi and I. Juhan-Vague, “PAI-1 and the metabolic syndrome: links, causes, and consequences,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2200–2207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. P. G. Arndt, S. K. Young, and G. S. Worthen, “Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway,” The Journal of Immunology, vol. 175, no. 6, pp. 4049–4059, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Agirbasli, M. Eren, S. Yasar et al., “Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo,” Journal of Thrombosis and Thrombolysis, vol. 38, no. 1, pp. 50–56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. W. L. Chandler, “A kinetic model of the circulatory regulation of tissue plasminogen activator,” Thrombosis and Haemostasis, vol. 66, no. 3, pp. 321–328, 1991. View at Google Scholar · View at Scopus
  49. J. K. Jensen and P. G. W. Gettins, “High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling,” Protein Science, vol. 17, no. 10, pp. 1844–1849, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Kaikita, A. B. Fogo, L. Ma, J. A. Schoenhard, N. J. Brown, and D. E. Vaughan, “Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition,” Circulation, vol. 104, no. 7, pp. 839–844, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Kaikita, J. A. Schoenhard, C. A. Painter et al., “Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition,” Journal of Molecular and Cellular Cardiology, vol. 34, no. 6, pp. 617–627, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. A. M. Thögersen, J.-H. Jansson, K. Boman et al., “High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor,” Circulation, vol. 98, no. 21, pp. 2241–2247, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Hamsten, G. Walldius, A. Szamosi et al., “Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction,” The Lancet, vol. 2, no. 8549, pp. 3–9, 1987. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Hamsten, B. Wiman, U. de Faire, and M. Blomback, “Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction,” The New England Journal of Medicine, vol. 313, no. 25, pp. 1557–1563, 1985. View at Publisher · View at Google Scholar · View at Scopus
  55. I. Juhan-Vague, M. C. Alessi, P. Joly et al., “Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response,” Arteriosclerosis, vol. 9, no. 3, pp. 362–367, 1989. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Schneiderman, M. S. Sawdey, M. R. Keeton et al., “Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 15, pp. 6998–7002, 1992. View at Publisher · View at Google Scholar · View at Scopus
  57. M. K. V. Durand, J. S. Bödker, A. Christensen et al., “Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis,” Thrombosis and Haemostasis, vol. 91, no. 3, pp. 438–449, 2004. View at Google Scholar · View at Scopus
  58. P. A. Andreasen, R. Egelund, and H. H. Petersen, “The plasminogen activation system in tumor growth, invasion, and metastasis,” Cellular and Molecular Life Sciences, vol. 57, no. 1, pp. 25–40, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. H. R. Lijnen, “Pleiotropic functions of plasminogen activator inhibitor-1,” Journal of Thrombosis and Haemostasis, vol. 3, no. 1, pp. 35–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. D. A. Lawrence, S. T. Olson, S. Palaniappan, and D. Ginsburg, “Engineering plasminogen activator inhibitor 1 mutants with increased functional stability,” Biochemistry, vol. 33, no. 12, pp. 3643–3648, 1994. View at Publisher · View at Google Scholar · View at Scopus
  61. M. B. Berkenpas, D. A. Lawrence, and D. Ginsburg, “Molecular evolution of plasminogen activator inhibitor-1 functional stability,” The EMBO Journal, vol. 14, no. 13, pp. 2969–2977, 1995. View at Google Scholar · View at Scopus
  62. M. Eren, C. A. Painter, J. B. Atkinson, P. J. Declerck, and D. E. Vaughan, “Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1,” Circulation, vol. 106, no. 4, pp. 491–496, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. P. J. Declerck, M. De Mol, D. E. Vaughan, and D. Collen, “Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator,” Journal of Biological Chemistry, vol. 267, no. 17, pp. 11693–11696, 1992. View at Google Scholar · View at Scopus
  64. T. Urano, L. Strandberg, L. B.-A. Johansson, and T. Ny, “A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate,” European Journal of Biochemistry, vol. 209, no. 3, pp. 985–992, 1992. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Loebermann, R. Tokuoka, J. Deisenhofer, and R. Huber, “Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function,” Journal of Molecular Biology, vol. 177, no. 3, pp. 531–557, 1984. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Mottonen, A. Strand, J. Symersky et al., “Structural basis of latency in plasminogen activator inhibitor-1,” Nature, vol. 355, no. 6357, pp. 270–273, 1992. View at Publisher · View at Google Scholar · View at Scopus
  67. T. J. Stout, H. Graham, D. I. Buckley, and D. J. Matthews, “Structures of active and latent PAI-1: a possible stabilizing role for chloride ions,” Biochemistry, vol. 39, no. 29, pp. 8460–8469, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. J. A. Huntington, R. J. Read, and R. W. Carrell, “Structure of a serpin-protease complex shows inhibition by deformation,” Nature, vol. 407, no. 6806, pp. 923–926, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. J. D. Shore, D. E. Day, A. M. Francis-Chmura et al., “A fluorescent probe study of plasminogen activator inhibitor-1: evidence for reactive center loop insertion and its role in the inhibitory mechanism,” Journal of Biological Chemistry, vol. 270, no. 10, pp. 5395–5398, 1995. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Egelund, K. W. Rodenburg, P. A. Andreasen, M. S. Rasmussen, R. E. Guldberg, and T. E. Petersen, “An ester bond linking a fragment of a serine proteinase to its serpin inhibitor,” Biochemistry, vol. 37, no. 18, pp. 6375–6379, 1998. View at Publisher · View at Google Scholar · View at Scopus
  71. A.-M. Audenaert, I. Knockaert, D. Collen, and P. J. Declerck, “Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop,” The Journal of Biological Chemistry, vol. 269, no. 30, pp. 19559–19564, 1994. View at Google Scholar · View at Scopus
  72. B. De Taeye, A. Gils, and P. J. Declerck, “The story of the serpin plasminogen activator inhibitor I: is there any need for another mutant?” Thrombosis and Haemostasis, vol. 92, no. 5, pp. 898–924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. H. M. Tucker, J. Mottonen, E. J. Goldsmith, and R. D. Gerard, “Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition,” Nature Structural & Molecular Biology, vol. 2, no. 6, pp. 442–445, 1995. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Munch, C. W. Heegaard, and P. A. Andreasen, “Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor,” Biochimica et Biophysica Acta—Protein Structure and Molecular Enzymology, vol. 1202, no. 1, pp. 29–37, 1993. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Kjøller, P. M. Martensen, L. Sottrup-Jensen, J. Justesen, K. W. Rodenburg, and P. A. Andreasen, “Conformational changes of the reactive-centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1,” European Journal of Biochemistry, vol. 241, no. 1, pp. 38–46, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. P. A. Andreasen, R. Egelund, S. Jensen, and K. W. Rodenburg, “Solvent effects on activity and conformation of plasminogen activator inhibitor-1,” Thrombosis and Haemostasis, vol. 81, no. 3, pp. 407–414, 1999. View at Google Scholar · View at Scopus
  77. S. Debrock and P. J. Declerck, “Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms,” Biochimica et Biophysica Acta—Protein Structure and Molecular Enzymology, vol. 1337, no. 2, pp. 257–266, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. A.-P. Bijnens, A. Gils, I. Knockaert, J. M. Stassen, and P. J. Declerck, “Importance of the hinge region between α-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies,” Journal of Biological Chemistry, vol. 275, no. 9, pp. 6375–6380, 2000. View at Publisher · View at Google Scholar · View at Scopus
  79. A. P. Bijnens, T. H. Ngo, A. Gils et al., “Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1,” Thrombosis and Haemostasis, vol. 85, no. 5, pp. 866–874, 2001. View at Google Scholar · View at Scopus
  80. S. L. Schousboe, R. Egelund, T. Kirkegaard, K. T. Preissner, K. W. Rodenburg, and P. A. Andreasen, “Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against α-helix F,” Thrombosis and Haemostasis, vol. 83, no. 5, pp. 742–751, 2000. View at Google Scholar · View at Scopus
  81. T. Wind, M. A. Jensen, and P. A. Andreasen, “Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding,” European Journal of Biochemistry, vol. 268, no. 4, pp. 1095–1106, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. J. P. Bastard, L. Piéroni, and B. Hainque, “Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance,” Diabetes/Metabolism Research and Reviews, vol. 16, no. 3, pp. 192–201, 2000. View at Publisher · View at Google Scholar
  83. M. Cesari, M. Pahor, and R. A. Incalzi, “Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions,” Cardiovascular Therapeutics, vol. 28, no. 5, pp. e72–e91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. D. J. Crutchley, G. V. McPhee, M. F. Terris, and M. A. Canossa-Terris, “Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 9, no. 6, pp. 934–939, 1989. View at Google Scholar · View at Scopus
  85. Y. Kobayashi, Y. Fukuo, T. Shibuya, and A. Terashi, “The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects,” Japanese Journal of Geriatrics, vol. 27, no. 5, pp. 578–583, 1990. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Madan, B. Gupta, S. Saluja, U. C. Kansra, B. K. Tripathi, and B. P. Guliani, “Coagulation profile in diabetes and its association with diabetic microvascular complications,” Journal of Association of Physicians of India, vol. 58, no. 8, pp. 481–484, 2010. View at Google Scholar · View at Scopus
  87. A. A. M. Adly, N. S. Elbarbary, E. A. R. Ismail, and S. R. Hassan, “Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness,” Journal of Diabetes and its Complications, vol. 28, no. 3, pp. 340–347, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. H. C. Kwaan, A. P. Mazar, and B. J. McMahon, “The apparent uPA/PAI-1 paradox in cancer: more than meets the eye,” in Seminars in Thrombosis and Hemostasis, Thieme Medical Publishers, 2013.
  89. A. Knudsen, T. L. Katzenstein, T. Benfield et al., “Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals,” AIDS, vol. 28, no. 8, pp. 1171–1179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Ferroni, M. Roselli, I. Portarena et al., “Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer—relationship with clinical outcome,” Anticancer Research, vol. 34, no. 3, pp. 1153–1161, 2014. View at Google Scholar · View at Scopus
  91. R. Schleef, D. L. Higgins, E. Pillemer, and L. J. Levitt, “Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor,” The Journal of Clinical Investigation, vol. 83, no. 5, pp. 1747–1752, 1989. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Dieval, G. Nguyen, S. Gross, J. Delobel, and E. K. O. Kruithof, “A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1,” Blood, vol. 77, no. 3, pp. 528–532, 1991. View at Google Scholar · View at Scopus
  93. W. P. Fay, A. D. Shapiro, J. L. Shih, R. R. Schleef, and D. Ginsburg, “Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation,” The New England Journal of Medicine, vol. 327, no. 24, pp. 1729–1733, 1992. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Ågren, B. Wiman, V. Stiller et al., “Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis,” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 201–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Kuhli, M. Lüchtenberg, I. Scharrer, and L.-O. Hattenbach, “Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 10, pp. 963–966, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. M. H. Lee, E. Vosburgh, K. Anderson, and J. McDonagh, “Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding,” Blood, vol. 81, no. 9, pp. 2357–2362, 1993. View at Google Scholar · View at Scopus
  97. H. Minowa, Y. Takahashi, T. Tanaka et al., “Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency,” Haemostasis, vol. 29, no. 5, pp. 286–291, 2000. View at Google Scholar · View at Scopus
  98. Y. Morimoto, A. Yoshioka, M. Sugimoto, Y. Imai, and T. Kirita, “Haemostatic management of intraoral bleeding in patients with von Willebrand disease,” Oral Diseases, vol. 11, no. 4, pp. 243–248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Repine and M. Osswald, “Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review,” Clinical and Applied Thrombosis/Hemostasis, vol. 10, no. 3, pp. 293–296, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Santamaría, M. Borrell, J. Mateo, C. Vallve, and J. Fontcuberta, “What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population,” Journal of Thrombosis and Haemostasis, vol. 5, no. 7, pp. 1565–1566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Takahashi, T. Tanaka, H. Minowa et al., “Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency,” International Journal of Hematology, vol. 64, no. 1, pp. 61–68, 1996. View at Publisher · View at Google Scholar · View at Scopus
  102. L. K. Tanimura, J. A. Weddell, C. G. McKown, A. D. Shapiro, and J. Mulherin, “Oral management of a patient with a plasminogen activator inhibitor (PAI-1) deficiency: case report,” Pediatric Dentistry, vol. 16, no. 2, pp. 133–135, 1994. View at Google Scholar · View at Scopus
  103. Z. Y. Zhang, Z. Y. Wang, N. Z. Dong, X. Bai, W. Zhang, and C. G. Ruan, “A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide,” Blood Coagulation and Fibrinolysis, vol. 16, no. 1, pp. 79–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Lindahl and B. Wiman, “Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium,” Biochimica et Biophysica Acta—Protein Structure and Molecular Enzymology, vol. 994, no. 3, pp. 253–257, 1989. View at Publisher · View at Google Scholar · View at Scopus
  105. C. M. Hekman and D. J. Loskutoff, “Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants,” The Journal of Biological Chemistry, vol. 260, no. 21, pp. 11581–11587, 1985. View at Google Scholar · View at Scopus
  106. D. E. Vaughan, P. J. Declerck, E. Van Houtte, M. De Mol, and D. Collen, “Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo,” Circulation Research, vol. 67, no. 5, pp. 1281–1286, 1990. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Ehnebom, P. Björquist, J.-O. Andersson, T. Johansson, and J. Deinum, “Detergent tween 80 modifies the specific activity of PAI-1,” Fibrinolysis and Proteolysis, vol. 11, no. 3, pp. 165–170, 1997. View at Google Scholar · View at Scopus
  108. O. Fjellström, J. Deinum, T. Sjögren et al., “Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation,” The Journal of Biological Chemistry, vol. 288, no. 2, pp. 873–885, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. I. Verhamme, J.-O. Kvassman, D. Day et al., “Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding,” Journal of Biological Chemistry, vol. 274, no. 25, pp. 17511–17517, 1999. View at Publisher · View at Google Scholar · View at Scopus
  110. D. M. Dupont, G. E. Blouse, M. Hansen et al., “Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached β-strand 1C,” Journal of Biological Chemistry, vol. 281, no. 47, pp. 36071–36081, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. T. L. Lindahl, O. Sigurdardottir, and B. Wiman, “Stability of plasminogen activator inhibitor 1 (PAI-1),” Thrombosis and Haemostasis, vol. 62, no. 2, pp. 748–751, 1989. View at Google Scholar · View at Scopus
  112. E. Sancho, D. W. Tonge, R. C. Hockney, and N. A. Booth, “Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli,” European Journal of Biochemistry, vol. 224, no. 1, pp. 125–134, 1994. View at Publisher · View at Google Scholar · View at Scopus
  113. J.-O. Kvassman, D. A. Lawrence, and J. D. Shore, “The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into β-sheet A,” Journal of Biological Chemistry, vol. 270, no. 46, pp. 27942–27947, 1995. View at Publisher · View at Google Scholar · View at Scopus
  114. H. Mångs, G.-C. Sui, and B. Wiman, “PAI-1 stability: the role of histidine residues,” FEBS Letters, vol. 475, no. 3, pp. 192–196, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. J. Keijer, M. Linders, H. Ehrlich, R. Klein Gebbink, and H. Pannekoe k, “Stabilisation of Plasminogen activator inhibitor type 1 (PAI-1) activity by arginine: possible implications for the interaction of PAI-1 with vitronectin,” Fibrinolysis, vol. 4, no. 3, pp. 153–159, 1990. View at Publisher · View at Google Scholar · View at Scopus
  116. D. E. Vaughan, P. J. Declerck, E. van Houtte, M. de Mol, and D. Collen, “Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo,” Thrombosis and Haemostasis, vol. 68, no. 1, pp. 60–63, 1992. View at Google Scholar · View at Scopus
  117. J. W. J. Lambers, M. Cammenga, B. W. Konig, K. Mertens, H. Pannekoek, and J. A. Van Mourik, “Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids,” The Journal of Biological Chemistry, vol. 262, no. 36, pp. 17492–17496, 1987. View at Google Scholar · View at Scopus
  118. K. Katagiri, K. Okada, H. Hattori, and M. Yano, “Bovine endothelial cell plasminogen activator inhibitor. Purification and heat activation,” European Journal of Biochemistry, vol. 176, no. 1, pp. 81–87, 1988. View at Publisher · View at Google Scholar · View at Scopus
  119. I. Schvartz, D. Seger, and S. Shaltiel, “Vitronectin,” The International Journal of Biochemistry and Cell Biology, vol. 31, no. 5, pp. 539–544, 1999. View at Publisher · View at Google Scholar · View at Scopus
  120. P. J. Declerck, M. de Mol, M.-C. Alessi et al., “Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin),” The Journal of Biological Chemistry, vol. 263, no. 30, pp. 15454–15461, 1988. View at Google Scholar · View at Scopus
  121. K. T. Preissner, J. Grulich-Henn, H. J. Ehrlich et al., “Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin,” Journal of Biological Chemistry, vol. 265, no. 30, pp. 18490–18498, 1990. View at Google Scholar · View at Scopus
  122. D. Seiffert, N. N. Wagner, and D. J. Loskutoff, “Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor,” Journal of Cell Biology, vol. 111, no. 3, pp. 1283–1291, 1990. View at Publisher · View at Google Scholar · View at Scopus
  123. G.-C. Sui and B. Wiman, “Stability of plasminogen activator inhibitor-1: role of tyrosine221,” FEBS Letters, vol. 423, no. 3, pp. 319–323, 1998. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Boncela, I. Papiewska, I. Fijalkowska, B. Walkowiak, and C. S. Cierniewski, “Acute phase protein α1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35305–35311, 2001. View at Publisher · View at Google Scholar · View at Scopus
  125. N. Vleugels, A. Gils, S. Mannaerts, I. Knockaert, and P. J. Declerck, “Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant,” Fibrinolysis and Proteolysis, vol. 12, no. 5, pp. 277–282, 1998. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Dewilde, S. V. Strelkov, A. Rabijns, and P. J. Declerck, “High quality structure of cleaved PAI-1-stab,” Journal of Structural Biology, vol. 165, no. 2, pp. 126–132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. A. A. Stoop, E. Eldering, T. R. Dafforn, R. J. Read, and H. Pannekoek, “Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries,” Journal of Molecular Biology, vol. 305, no. 4, pp. 773–783, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Chorostowska-Wynimko, R. Swiercz, E. Skrzypczak-Jankun, A. Wojtowicz, S. H. Selman, and J. Jankun, “A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis,” Molecular Cancer Therapeutics, vol. 2, no. 1, pp. 19–28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. H. Brogren, C. Sihlbom, K. Wallmark et al., “Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin,” Thrombosis Research, vol. 122, no. 2, pp. 271–281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. D. Lawrence, L. Strandberg, T. Grundstrom, and T. Ny, “Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells,” European Journal of Biochemistry, vol. 186, no. 3, pp. 523–533, 1989. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Gils, I. Knockaert, E. Brouwers, and P. J. Declerck, “Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations,” Fibrinolysis and Proteolysis, vol. 14, no. 1, pp. 58–64, 2000. View at Publisher · View at Google Scholar · View at Scopus
  132. Y. Xue, P. Björquist, T. Inghardt et al., “Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide,” Structure, vol. 6, no. 5, pp. 627–636, 1998. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Gils, K. E. Pedersen, P. Skottrup et al., “Biochemical importance of glycosylation of plasminogen activator inhibitor-1,” Thrombosis and Haemostasis, vol. 90, no. 2, pp. 206–217, 2003. View at Google Scholar · View at Scopus
  134. C.-C. Lee and T.-S. Huang, “Plasminogen activator inhibitor-1: the expression, biological functions, and effects on tumorigenesis and tumor cell adhesion and migration,” Journal of Cancer Molecules, vol. 1, no. 1, pp. 25–36, 2005. View at Google Scholar
  135. R. Serrano, J. Barrenetxe, J. Orbe et al., “Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 297, no. 5, pp. R1563–R1569, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Bager, J. S. Johansen, J. K. Jensen et al., “Protein conformational change delayed by steric hindrance from an N-linked glycan,” Journal of Molecular Biology, vol. 425, no. 16, pp. 2867–2877, 2013. View at Publisher · View at Google Scholar · View at Scopus
  137. T. Skurk and H. Hauner, “Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1,” International Journal of Obesity, vol. 28, no. 11, pp. 1357–1364, 2004. View at Publisher · View at Google Scholar · View at Scopus